CAPTIVATE – Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition
Eric de Groot - Imagelabonline & Cardiovascular, Eindhoven and Lunteren, the Netherlands
The Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition (CAPTIVATE) is a two-arm clinical trial based at 40 lipid clinics in the USA, Canada, Europe, South Africa, and Israel. The principal aim of the trial was to investigate the effect of Pactimibe (100mg/day) versus placebo on progression of carotid artery disease in individuals with heterozygous familial hypercholesterolaemia. Individuals were eligible for inclusion if they were diagnosed with heterozygous familial hypercholesterolaemia, had a calculated LDL-C level greater than or equal to 100mg/dL, had triglycerides less than 500mg/dL, and were on usual and stable lipid-lowering therapy. The protocol was reviewed and approved by the institutional review board at each of the participating centres and all participants provided written informed consent before entry into the trial.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT00151788
ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia: The CAPTIVATE Randomized Trial. JAMA. 2009 Mar 18;301(11):1131-9